ZA200906179B - Pharmaceutical formulations of GHRH molecules - Google Patents

Pharmaceutical formulations of GHRH molecules

Info

Publication number
ZA200906179B
ZA200906179B ZA200906179A ZA200906179A ZA200906179B ZA 200906179 B ZA200906179 B ZA 200906179B ZA 200906179 A ZA200906179 A ZA 200906179A ZA 200906179 A ZA200906179 A ZA 200906179A ZA 200906179 B ZA200906179 B ZA 200906179B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical formulations
ghrh molecules
ghrh
molecules
formulations
Prior art date
Application number
ZA200906179A
Other languages
English (en)
Inventor
Helen Loughrey
Byeong Chang
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of ZA200906179B publication Critical patent/ZA200906179B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200906179A 2007-04-04 2009-09-07 Pharmaceutical formulations of GHRH molecules ZA200906179B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90998507P 2007-04-04 2007-04-04

Publications (1)

Publication Number Publication Date
ZA200906179B true ZA200906179B (en) 2010-05-26

Family

ID=39827484

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200906179A ZA200906179B (en) 2007-04-04 2009-09-07 Pharmaceutical formulations of GHRH molecules

Country Status (13)

Country Link
US (1) US20080249017A1 (enExample)
EP (1) EP2142207A4 (enExample)
JP (1) JP2010523501A (enExample)
KR (1) KR20090130044A (enExample)
CN (1) CN101678083A (enExample)
AU (1) AU2008235215A1 (enExample)
BR (1) BRPI0809441A2 (enExample)
CA (1) CA2680329A1 (enExample)
IL (1) IL200810A0 (enExample)
MX (1) MX2009010675A (enExample)
RU (1) RU2009140731A (enExample)
WO (1) WO2008122118A1 (enExample)
ZA (1) ZA200906179B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615173C (en) 2005-07-14 2012-01-03 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
JP2010506941A (ja) * 2006-10-17 2010-03-04 リセラ,インク. 甲状腺眼症の治療のための方法、組成物及び製剤
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
GB2487868B (en) * 2010-01-15 2014-12-10 Neothetics Inc Lyophilized cake formulations
JP5582983B2 (ja) * 2010-11-24 2014-09-03 楠本化成株式会社 水系沈降防止剤
UA111822C2 (uk) 2010-11-24 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Новамедіка" Монотерапевтичий препарат селективного ліпофільного бета-агоніста тривалої дії і спосіб косметичного лікування ожиріння і контурного випинання
JP2016027003A (ja) * 2012-11-20 2016-02-18 大蔵製薬株式会社 長期間安定なオランザピンの水性医薬製剤
US8871713B2 (en) * 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
SG11202110469PA (en) * 2019-03-29 2021-10-28 Massachusetts Gen Hospital Ghrh or analogues thereof for use in treatment of hepatic disease
CN115884783A (zh) * 2020-07-05 2023-03-31 瑟瑞技术公司 Ghrh类似物的低剂量药物组合物及其用途
WO2024133908A1 (en) * 2022-12-23 2024-06-27 Syna Therapeutics, S.L. Stable pharmaceutical compositions comprising romiplostim

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137872A (en) * 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
EP0880969A1 (en) * 1997-05-28 1998-12-02 Applied Research Systems ARS Holdings N.V. Pharmaceutical compositions of peptides having low solubility in physiological medium
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
AU5247599A (en) * 1998-07-30 2000-02-21 Point Biomedical Corporation A novel excipient for the lyophilization of aqueous suspensions of microparticles
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
US20020061838A1 (en) * 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
CA2422707A1 (en) * 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
WO2003068805A2 (en) * 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
KR20050071498A (ko) * 2002-09-18 2005-07-07 상트르 오스피딸리에 드 루니버시떼 드 몬트리알 성장 호르몬 방출 호르몬 유사체
WO2004105789A1 (en) * 2003-05-29 2004-12-09 Theratechnologies Inc. Grf analog compositions and their use
BRPI0508798A (pt) * 2004-04-07 2007-09-04 Ares Trading Sa formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento
KR101228229B1 (ko) * 2004-10-20 2013-01-31 쎄러테크놀로지스 인코포레이티드 성장 호르몬 분비 촉진물질 및 그의 용도
CA2593112A1 (en) * 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion

Also Published As

Publication number Publication date
IL200810A0 (en) 2010-05-17
RU2009140731A (ru) 2011-05-10
EP2142207A4 (en) 2013-01-16
WO2008122118A1 (en) 2008-10-16
US20080249017A1 (en) 2008-10-09
KR20090130044A (ko) 2009-12-17
JP2010523501A (ja) 2010-07-15
MX2009010675A (es) 2009-10-23
AU2008235215A2 (en) 2011-02-24
EP2142207A1 (en) 2010-01-13
CA2680329A1 (en) 2008-10-16
AU2008235215A1 (en) 2008-10-16
BRPI0809441A2 (pt) 2015-06-23
CN101678083A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
IL200810A0 (en) Pharmaceutical formulations of ghrh molecules
HUS1800007I1 (hu) Gyógyászati készítmény
IL247741A0 (en) pharmaceutical preparations
IL200198A0 (en) Formulations of lipophilic bioactive molecules
EP2133095A4 (en) PHARMACEUTICAL COMPOSITION
EP2133094A4 (en) PHARMACEUTICAL COMPOSITION
EP2222313A4 (en) PHARMACEUTICAL COMPOSITIONS
PL2966175T3 (pl) Kompozycje farmaceutyczne zawierające 17-alfa-propionian korteksolonu
IL200125A0 (en) Pharmaceutical composition
EP2224805A4 (en) PHARMACEUTICAL COMPOSITION
EP2224915A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0707127D0 (en) Pharmaceutical compositions
EP2224808A4 (en) PHARMACEUTICAL COMPOSITION
EP2146695A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0709811D0 (en) Pharmaceutical compositions
GB0712454D0 (en) Pharmaceutical compositions
IL205975A0 (en) Pharmaceutical composition
IL205931A0 (en) Pharmaceutical composition
HK1139323A (en) Pharmaceutical formulations of ghrh molecules
GB2454923B (en) Pharmaceutical compositions
IL201394A0 (en) Niacin - based pharmaceutical compositions
HU0700755D0 (en) Pharmaceutical compositions containing capsaicionid
GB0713093D0 (en) Pharmaceutical formulations
GB0813031D0 (en) Pharmaceutical formulations
GB0810217D0 (en) Pharmaceutical formulations